VisionPoint Advisory Group LLC Has $2.44 Million Stock Holdings in Fresenius Medical Care AG (NYSE:FMS)

VisionPoint Advisory Group LLC reduced its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 24.7% in the 4th quarter, Holdings Channel reports. The firm owned 110,269 shares of the company’s stock after selling 36,114 shares during the period. VisionPoint Advisory Group LLC’s holdings in Fresenius Medical Care were worth $2,442,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FMS. Allworth Financial LP increased its stake in shares of Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Fresenius Medical Care in the third quarter valued at about $38,000. Venturi Wealth Management LLC grew its position in Fresenius Medical Care by 1,045.8% in the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after acquiring an additional 4,800 shares during the last quarter. GAMMA Investing LLC raised its stake in Fresenius Medical Care by 43.3% during the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after acquiring an additional 2,166 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC bought a new position in shares of Fresenius Medical Care in the fourth quarter worth about $201,000. 8.37% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Truist Financial lifted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Berenberg Bank began coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective on the stock. Finally, Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd.

Fresenius Medical Care Price Performance

FMS stock opened at $22.94 on Friday. The company has a market capitalization of $13.46 billion, a P/E ratio of 18.96, a PEG ratio of 0.77 and a beta of 0.93. The company has a fifty day moving average price of $23.42 and a 200-day moving average price of $21.63. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.